You are in: HOME PAGE / Elisa / Eu-tTG

The identification of tissue transglutaminase as the antigen responsible for endomysial positivity has opened up new horizons for the serological diagnosis of celiac disease. Today the determination of anti-tTG antibodies is the reference test for the diagnosis and follow-up of this disease.

  • Eu-tTG IgA New - code 9105, 96 test
    It has been proven that tissue transglutaminase (tTG) is the endomysial autoantigen of coeliac disease.(1)
    Eu-tTG New is the standardised immunological determination of anti-tTG antibodies, recently indicated by the scientific community as the reference test for the diagnosis and follow-up of coeliac disease.
  • Eu-tTG IgG New - code 9106, 96 test
    Eu-tTG New can play a fundamental role in both large and specific screening projects, especially for mono-symptomatic or atypical cases where symptoms can be attributed to coeliac disease such as: recurrent abortions, teeth enamel hypoplasia, alopecia, osteoporosis, type I diabetes mellitus, sterility, sideropenic anaemia resistant to iron therapy, epilepsy and others.

Features of the products

  • Human recombinant antigen obtained from prokaryotic cells (E.coli)
    to avoid cross-reaction with nuclear eukaryotic antigens
  • Calibration curve for a proper patient follow-up
  • Ready-to-use reagents
  • Unique sample dilution for both IgA and IgG (1:101)
  • Total incubation time: 90 minutes at room temperature
  • Products manufactured and commercialised by Eurospital, based on the invention of the German scientists Schuppan and Dieterich who provided Eurospital with exclusive world wide licence of use

FDA Clearance

Eu-tTG IgA and IgG, reference kits for the detection of class IgA and IgG antibodies against human tissue transglutaminase, have obtained the FDA 510k clearance on February 7th 2011 (K102964).

Eurospital Spa - Via Flavia 122 - 34147 Trieste - P.IVA: 00047510326 - C.S. € 2582000 CF e Reg. Impr. 00047510326 - REA TS 38955
Eurospital © 2019 - Privacy - Site credits